Dare Bioscience (DARE) EBITDA (2016 - 2026)

Dare Bioscience (DARE) has reported EBITDA for 11 consecutive years, with -$3.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 22.46% year-over-year to -$3.0 million; the trailing twelve-month figure through Jun 2026 stood at -$11.9 million (up 35.39% YoY), and the FY2025 full-year result was -$13.6 million, up 42.21% from the prior year.
• EBITDA slipped to -$3.0 million in Q2 2026 per DARE's latest filing, from -$1.5 million in the prior quarter.
• Across five years, EBITDA topped out at $384322.0 in Q2 2022 and bottomed at -$16.2 million in Q4 2022.
• Historically, EBITDA has averaged -$6.0 million across 5 years, with a median of -$5.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBITDA soared 104.19% in 2022, then tumbled 2439.02% in 2023.
• Over 5 years, EBITDA stood at -$16.2 million in 2022, then surged by 68.14% to -$5.2 million in 2023, then declined by 4.19% to -$5.4 million in 2024, then soared by 72.69% to -$1.5 million in 2025, then tumbled by 101.73% to -$3.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.0 million, -$1.5 million, and -$3.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.